New PrEP Study: SeroPrEP

Colleagues at UCSF are conducting a study called SeroPrEP to characterize new HIV infections among persons using long-acting injectable cabotegravir (CAB-LA) or oral PrEP.

SeroPrEP is an observational (non-interventional) study that aims to evaluate causes of HIV acquisition on CAB-LA or oral PrEP via sensitive assays for ARV resistance, drug levels/pharmacokinetics (PK), and diagnostics; and assess subsequent HIV treatment outcomes on ART. The study is funded by the National Institutes of Health.

Participant eligibility criteria include:

• One or more HIV tests suggesting that HIV-1 infection has occurred (e.g. Ag/Ab, RNA)
• Use/receipt of CAB-LA in the past 18 months or oral PrEP in the past 3 months
• Age >= 18 years

The study involves:

• A brief online participant survey and e-consent
• A brief online clinician survey
• Collection of blood, urine, and small scalp hair samples
• A behavioral questionnaire
• Follow-up for up to 12 months in the study to assess ART outcomes 

SeroPrEP enrolls participants from all 50 U.S. states and Puerto Rico. Patients who enroll in the study receive a $50 gift card for each study visit.

Enrollment information can be found on our study website. See below for a Study Flyer, Study Slide and Dear Provider letter – please circulate these to your colleagues who may have patients eligible for the study.

Click below to download the Sero PrEP

Click below to download the SeroPrEP Dear Doctor Letter:

Click below to download the SeroPrEP Overview Slide:

Please let the SeroPrEP study team know if it would be possible to include their study information in your newsletters/network communications, or to include their study slide in trainings related to long-acting HIV prevention, PrEP, or HIV testing.

Contact Information:

The SeroPrEP team

Catherine Koss, MD; Urvi Parikh, PhD;

Monica Gandhi, MD, MPH; Lisa Georgetti Gomez, MSPH 

seroprep.ucsf.edu | seroprep@ucsf.edu | (415) 539-5688